Menu

Blog

Search results for 'Nicholi'

Jun 9, 2020

Help for Nicholi

Posted by in categories: biotech/medical, health, lifeboat

Posted with permission by Eric Klien.

Hello everyone, as some of you may be aware about 6 years ago I was diagnosed with multiple myeloma and I published about it on Lifeboat Foundation’s blog. I was in remission but relapsed about a year ago. Going through radiation therapy as well as chemotherapy has taken its toll on my health and with the recent outbreak of Covid-19 has really put a lot of us in the high risk category. In order to stay safe i have avoided working for 3 months. Because of these unfortunate circumstances I am kindly requesting that anyone who is willing to help me get back on my feet to please help donate to my GoFund me page: https://www.gofundme.com/f/help-for-nicholi

I sincerely appreciate any and all help available. Thank you! I will post a link to my journey with cancer published on Lifeboat Foundation’s blog.

Continue reading “Help for Nicholi” »

Aug 28, 2021

Scientists propose a novel approach to treating Alzheimer’s disease and other related diseases

Posted by in categories: biotech/medical, neuroscience

Jul 28, 2021

This 20-person biotech firm just beat Elon Musk’s Neuralink in getting the OK to test brain chip implants in humans with paralysis

Posted by in categories: biotech/medical, computing, Elon Musk, neuroscience

Synchron has beat rival Neuralink to human trials of its “implantable brain computer interface.”

The chip will be studied in six patients later this year as a possible aid for paralyzed people.

Elon Musk previously used Neuralink’s chip in a monkey, which then played video games with its mind.

Continue reading “This 20-person biotech firm just beat Elon Musk’s Neuralink in getting the OK to test brain chip implants in humans with paralysis” »

Jul 1, 2021

RedHill Biopharma reports preliminary results from new preclinical study showing potent inhibition of COVID-19 variants

Posted by in category: biotech/medical

Preliminary results showed potent inhibition of both the Beta and Gamma variants by opaganib at non-cytotoxic doses, the company said.

Opaganib is a unique host-targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of COVID-19.

Jun 17, 2021

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214

Posted by in category: biotech/medical

This looks extremely promising:


SAN DIEGO, June 17, 2021 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced results from the company’s Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK0214, a novel, orally available small molecule thyroid receptor beta (TRβ) agonist in development for the potential treatment for X-linked adrenoleukodystrophy (X-ALD). In this study, VK0214 demonstrated encouraging safety and tolerability, as well as a predictable pharmacokinetic (PK) profile. The company expects to initiate a Phase 1b study of VK0214 in patients with X-ALD in the coming weeks.

The Phase 1 trial was a randomized, double-blind, placebo-controlled study in healthy volunteers. The primary objective of the study was to evaluate the safety and tolerability of VK0214 administered orally for up to 14 days. The secondary objective was to evaluate the pharmacokinetics of VK0214 following single and multiple oral doses. The first portion of the study evaluated single doses of VK0214; in the second portion of the study subjects received VK0214 once daily for 14 days. Subsequent cohorts in both parts of the study received successively higher VK0214 doses.

VK0214 was shown to be safe and well-tolerated at all doses evaluated in this study. No serious adverse events were reported, and no treatment or dose-related trends were observed for vital signs, gastrointestinal effects, cardiovascular measures, or physical examinations. VK0214 demonstrated dose-dependent exposures, no evidence of accumulation following multiple doses, and a half-life consistent with anticipated once-daily dosing regimens.

Continue reading “Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214” »

Jun 4, 2021

‘Next big wave’: Radiation drugs track and kill cancer cells

Posted by in category: biotech/medical

Doctors are reporting improved survival in men with advanced prostate cancer from an experimental drug that delivers radiation directly to tumor cells. Few such drugs are approved now, but the approach may become a new way to treat patients with other hard-to-reach or inoperable cancers.

Jun 3, 2021

Neuralink Brain Chip Will End Language in Five to 10 Years, Elon Musk Says

Posted by in categories: computing, Elon Musk, neuroscience

In a recent interview, Elon Musk stated that the human language could possibly end within five to ten years. The CEO of Neuralink went to talk with Joe Rogan, implying that with the innovation of the brain chip the company is currently developing, humans won’t have to speak anymore using traditional languages.


Neuralink develops a chip that will soon be able to attach to the human brain. The chip’s invention aimed to communicate faster and conveniently. Through a single universal language, Elon Musk believes that the way we talk today will soon improve. The brain chip is expected to be completed to be developed within a few years, and by then, our communication could possibly evolve.

Continue reading “Neuralink Brain Chip Will End Language in Five to 10 Years, Elon Musk Says” »

May 31, 2021

Cities Have Unique Microbial ‘Fingerprints’, First Study of Its Kind Reveals

Posted by in categories: biotech/medical, genetics

Each city is populated by a unique host of microbial organisms, and this microbial ‘fingerprint’ is so distinctive, the DNA on your shoe is likely enough to identify where you live, scientists say.

In a new study, researchers took thousands of samples from mass transit systems in 60 cities across the world, swabbing common touch points like turnstiles and railings in bustling subways and bus stations across the world.

Subjecting over 4700 of the collected samples to metagenomic sequencing (the study of genetic material collected from the environment), scientists created a global atlas of the urban microbial ecosystem, which they say is the first systematic catalog of its kind.

Continue reading “Cities Have Unique Microbial ‘Fingerprints’, First Study of Its Kind Reveals” »

May 31, 2021

Calculations Show Humans Can’t Contain Superintelligent Machines

Posted by in category: robotics/AI

Researchers say we’re unlikely to ever be able to contain a large enough superintelligent artificial intelligence.

The premise sounds scary, but knowing the odds will help scientists who work on these projects.

Self-teaching AI already exists and can teach itself things programmers don’t “fully understand.”

Continue reading “Calculations Show Humans Can’t Contain Superintelligent Machines” »

May 28, 2021

Had COVID? You’ll probably make antibodies for a lifetime

Posted by in category: biotech/medical

Many people who have been infected with SARS-CoV-2 will probably make antibodies against the virus for most of their lives. So suggest researchers who have identified long-lived antibody-producing cells in the bone marrow of people who have recovered from COVID-191.

The study provides evidence that immunity triggered by SARS-CoV-2 infection will be extraordinarily long-lasting. Adding to the good news, “the implications are that vaccines will have the same durable effect”, says Menno van Zelm, an immunologist at Monash University in Melbourne, Australia.

Antibodies — proteins that can recognize and help to inactivate viral particles — are a key immune defence. After a new infection, short-lived cells called plasmablasts are an early source of antibodies.

Page 1 of 3412345678